Most Popular News Stories on OBR Daily
The ten most read articles fromOBR Daily in the past month, updated continually:
(Bloomberg) June 28, 2017 - Test results for AstraZeneca Plc’s next-generation cancer therapy -- among the most anticipated in the pharmaceutical industry this year -- stand to rijig the order of dominance in a field led by Merck & Co.
(Reuters Health) June 29, 2017 - Experts tasked with identifying skin cancer in laboratories often disagree over diagnoses, according to a new study.
(FDA.gov) June 29, 2017 - The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
(Seattle Genetics) June 26, 2017 - Randomized Phase 3 clinical trial with Adcetris met primary endpoint, demonstrating a statistically significant improvement in modified progression-free survival; abstract to be submitted for presentation at the 2017 ASH annual meeting; regulatory submissions planned.
(Wall Street Journal) July 13, 2017 - More than a year after the National Institutes of Health published a study that criticized its own hospital, the renowned research facility continues to suffer the fallout, as the patient census lags and morale languishes.
(ASCO in Action) June 26, 2017 - ASCO’s delegates participated in the American Medical Association’s (AMA) annual House of Delegates (HOD) meeting to advocate on behalf of oncologists and patients with cancer on issues including utilization management, MACRA implementation, access to health insurance, and opioids.
(Bloomberg) June 30, 2017 - Donald Jones used to pay at least $500 a month for a brand-name drug, Gleevec, that’s kept his leukemia at bay for five years. Lately, he’s been paying almost as much for a generic version of the same pill.
(Bloomberg) July 7, 2017 - It’s a choice no doctor ever wants to make: which patient will get a chance to live, and which will not. That is a decision oncologists may soon confront when the first two products in a revolutionary new way to treat cancer reach the U.S. market this year.
(Reuters) July 17, 2017 - A U.S. appeals court ruled on Monday that a patent on Takeda Pharmaceutical Co Ltd's cancer treatment Velcade is valid, pushing back the date when generic drug makers including Teva Pharmaceutical Industries Ltd and Mylan NV will be allowed to launch lower-cost versions of the drug in the United States.
(Kaiser Health News) July 18, 2017 - The controversial 340B drug discount program for hospitals came under fire at a Congressional hearing.